2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-126415
    Magnesium Lithospermate B 122021-74-3 99.49%
    Magnesium Lithospermate B, is a derivative of caffeic acid tetramer and an inhibitor of Na+/K+ ATPase, which can be extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroin?ammation and attenuates neurodegeneration.
    Magnesium Lithospermate B
  • HY-12709A
    ARC 239 dihydrochloride 55974-42-0 99.57%
    ARC 239 dihydrochloride is a selective α2B/2C adrenoceptor antagonist (pKd values are 5.95, 7.41 and 7.56 at α2A, α2B, and α2C receptors respectively). ARC 239 dihydrochloride binds to CHO cell membranes expressing human recombinant a2A-, a2B- or a2C-adrenoceptor subtypes with pKis of 5.6, 8.4, and 7.08, respectively.
    ARC 239 dihydrochloride
  • HY-134258
    MEISi-1 446306-43-0 98.76%
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer.
    MEISi-1
  • HY-135326
    4-Propionamidophenol 1693-37-4 99.89%
    4-Propionamidophenol is an important intermediate of alkanolamine derivatives with β-adrenergic blocking activity. 4-Propionamidophenol can be used in the study of diseases such as heart disease and hypertension.
    4-Propionamidophenol
  • HY-13715C
    Norepinephrine tartrate 51-40-1 99.76%
    Norepinephrine (Levarterenol; L-Noradrenaline) tartrate is a potent adrenergic receptor (AR) agonist. Norepinephrine tartrate activates α1, α2, β1 receptors.
    Norepinephrine tartrate
  • HY-139690
    CCG258747 2615910-00-2 98.96%
    CCG258747 is a selective GRK2 inhibitor (IC50=18 nM) with high selectivity over GRK1, GRK5, PKA, and ROCK1 (518, 83, >5500, and >550–fold, respectively).CCG258747 also blocks the internalization of the µ-opioid receptor. G protein-coupled receptor (GPCR) kinases (GRKs) are attractive targets for the research of heart failure.
    CCG258747
  • HY-143220
    SS(no Galnac)-Inclisiran sodium
    SS(no Galnac)-Inclisiran (sodium) is a single stran Inclisiran with no GalNAc. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
    SS(no Galnac)-Inclisiran sodium
  • HY-145653
    GSK2647544 1380426-95-8 99.46%
    GSK2647544 is an orally available, selective inhibitor of Lp-PLA2. Lipoprotein-associated phospholipase (Lp-PLA2) is a calcium-independent phospholipase A2 with proinflammatory activities that is primarily secreted by monocyte-derived macrophages.
    GSK2647544
  • HY-148055
    Wnt/β-catenin agonist 3 912790-59-1 99.96%
    Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis.
    Wnt/β-catenin agonist 3
  • HY-148836
    c-Myc inhibitor 6 2768765-58-6 98.04%
    c-Myc inhibitor 6 (compound A102) is a c-Myc inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection.
    c-Myc inhibitor 6
  • HY-153335
    Enpp-1-IN-16 2289739-47-3 99.11%
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders.
    Enpp-1-IN-16
  • HY-160099
    20-5,14-HEDE 240427-86-5 98.34%
    20-5,14-HEDE is an analog of 20-HETE with anti-apoptosis activity. 20-5,14-HEDE can inhibit the increase of caspase-3 expression level and DNA fragmentation in pulmonary artery endothelial cells (BPAECs) under serum starvation conditions, thereby reducing cell apoptosis. 20-5,14-HEDE can be used in the study of cardiovascular diseases.
    20-5,14-HEDE
  • HY-B0491A
    Carbazochrome sodium sulfonate 51460-26-5 ≥98.0%
    Carbazochrome sodium sulfonate (AC-17) is a capillary stabiliser and used for the research of haemorrhage. Carbazochrome sodium sulfonate is an antihemorrhagic agent.
    Carbazochrome sodium sulfonate
  • HY-B1275A
    Cephalothin 153-61-7 99.34%
    Cephalothin (Cephalotin) is a semi-synthetic cephalosporin antibiotic and beta-lactam antibiotic. Cephalothin inhibits class C β-lactamase AmpC, with an Ki of 0.32 µM. Cephalothin binds to penicillin-binding proteins, interfering with the cross-linking of peptidoglycan in the cell wall and thus hindering the normal synthesis of the bacterial cell wall. Cephalothin shows antibacterial activity against a variety of bacteria. Cephalothin can be used in hematological and nephrotoxicity studies.
    Cephalothin
  • HY-B1610E
    Sodium citrate dihydrate, meets USP testing specifications 6132-04-3 ≥98.0%
    Sodium citrate dihydrate, meets USP testing specifications is an anticoagulant and also used as a buffer and food preservatives.
    Sodium citrate dihydrate, meets USP testing specifications
  • HY-P0207A
    Endothelin-2 (49-69), human TFA 98.78%
    Endothelin-2 (49-69), human (TFA) (Endothelin-2 (49-69) (human, canine) (TFA)) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, ET-RA and ET-RB.
    Endothelin-2 (49-69), human TFA
  • HY-P0314A
    Arg-Gly-Asp-Cys TFA 2171504-22-4 99.95%
    Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding.
    Arg-Gly-Asp-Cys TFA
  • HY-P1071A
    α-CGRP(human) TFA 98.44%
    α-CGRP(human) (TFA) is a regulatory neuropeptide of 37 amino acids. α-CGRP(human) (TFA) is widely distributed in the central and peripheral nervous system. α-CGRP(human) (TFA) is a potent vasodilator and has inotropic and chronotropic effects.
    α-CGRP(human) TFA
  • HY-P1082A
    Gap 26 TFA 99.51%
    Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.
    Gap 26 TFA
  • HY-P1163A
    D[LEU4,LYS8]-VP TFA 99.29%
    D[LEU4,LYS8]-VP TFA is a selective agonist of vasopressin V1b receptor, with the Kis of 0.16 nM, 0.52 nM, and 0.1.38 nM for rat, human and mouse V1b receptor, respectively. D[LEU4,LYS8]-VP TFA has weak antidiuretic, vasopressor, and in vitro oxytocic activities.
    D[LEU4,LYS8]-VP TFA
Cat. No. Product Name / Synonyms Application Reactivity